跳至主要内容
临床试验/NCT01763554
NCT01763554进行中(未招募)不适用

Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014

AHS Cancer Control Alberta1 个研究点 分布在 1 个国家目标入组 115 人开始时间: 2012年8月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
115
试验地点
1
主要终点
Efficacy data on subjects with neuroendocrine tumours (NET) treated with Lu-177 DOTA-TATE

研究概览

简要总结

Retrospective review of the medical files of 115 patients with neuroendocrine tumours who were treated with Lutetium-177 DOTA-TATE under Health Canada's Special Access Programme (SAP) at the Cross Cancer Institute between January 2010 and April 30, 2014. Efficacy, safety, and other relevant data will be collected to support a separate clinical trial application.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
14 Years 至 90 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Efficacy data on subjects with neuroendocrine tumours (NET) treated with Lu-177 DOTA-TATE

时间窗: Retrospective data January 2010 - April 30, 2014

Data (Radioisotope and CT/MRI images, blood assays and Quality of Life Questionnaires, pre and post treatment) will be collected to determine tumor response of subjects with NET after treatment with Lu-177 DOTA-TATE.

次要结局

  • Safety and other relevant information on subjects treated with Lu-177 DOTA-TATE(Retrospective data January 2010 - April 30, 2014)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验